Welcome to our dedicated page for Biote news (Ticker: BTMD), a resource for investors and traders seeking the latest updates and insights on Biote stock.
Biote Corp. (BTMD) operates in the specialized field of hormone optimization, offering growth practice-building solutions. The company's primary focus is to empower Biote-certified practitioners with the tools and knowledge required to establish, build, and effectively implement hormone optimization programs. These programs are designed to provide personalized solutions tailored to individual patient needs.
Biote Corp. provides a comprehensive suite of components to its practitioners, including training, marketing support, and ongoing education. This holistic approach ensures that practitioners are well-equipped to deliver high-quality care in the hormone optimization space. The company's commitment to education and support is a key differentiator, enabling practitioners to stay at the forefront of this rapidly evolving field.
Recent achievements by Biote Corp. include expanding its network of certified practitioners and forging new partnerships aimed at enhancing its service offerings. The company continues to invest in research and development to improve its products and services, ensuring that they meet the highest standards of efficacy and safety.
Financially, Biote Corp. has demonstrated steady growth, driven by the increasing demand for hormone optimization solutions. The company's strategic initiatives and robust business model have positioned it well to capitalize on emerging opportunities in the healthcare sector.
For those interested in the latest updates and developments from Biote Corp., the company regularly releases news and updates, which are accessible through various channels.
biote Corp. (Nasdaq: BTMD) announced that it will release its first quarter financial results on May 9, 2023, after market close. A conference call to discuss these results is set for May 10, 2023, at 8:30 a.m. ET. Investors can access the call via phone or a live webcast. Biote specializes in personalized hormone optimization therapies aimed at transforming healthy aging. The company operates within an $8 billion global market, focusing on training practitioners to address hormone-related aging conditions. The press release also includes forward-looking statements highlighting various risks, such as regulatory pressures and competition. Investors are encouraged to review Biote's Annual Report and other SEC filings for further details on risks and uncertainties.
Biote (NASDAQ: BTMD) announced the appointment of John Denne as General Manager of its Men’s Health Division, a move aimed at expanding the company's footprint in the male hormone replacement therapy market. Denne brings over 30 years of healthcare experience, having previously driven commercial success at Endo International in Men’s Health. Terry Weber, CEO of Biote, expressed excitement over Denne’s track record in brand recognition and sustainable growth. Denne echoed these sentiments, highlighting the significant opportunity in hormone replacement therapy for men, which remains largely unmet. Biote operates in a $7 billion global market focused on hormone optimization therapies, and this leadership change is anticipated to accelerate their growth initiatives.
Biote (NASDAQ: BTMD) announced strong financial results for Q4 and the full year 2022, achieving record revenue of $165.0 million and a 24.6% increase in Adjusted EBITDA to $50.1 million. The Q4 revenue rose 18.5% to $44.5 million, supported by a 40% increase in Adjusted EBITDA to $13.1 million. Despite a net income of $1.3 million, the company reported an operating loss of $60.7 million due to substantial stock compensation and transaction-related expenses. For 2023, Biote anticipates revenue between $190-$200 million and Adjusted EBITDA of $56-$60 million, reflecting a continued focus on growth and market expansion.
FAQ
What is the current stock price of Biote (BTMD)?
What is the market cap of Biote (BTMD)?
What does Biote Corp. do?
Who are Biote-certified practitioners?
What kind of support does Biote Corp. provide to practitioners?
What recent achievements has Biote Corp. made?
How does Biote Corp. ensure the quality of its hormone optimization solutions?
What is Biote Corp.'s financial condition?
How can I stay updated on Biote Corp.'s latest news?
What are the core components provided by Biote Corp. to practitioners?
Why is hormone optimization important?
Who can benefit from Biote Corp.'s hormone optimization programs?
